Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve In terms of Regulation ....
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has informed BSE and NSE that its Board of Directors will meet on Wednesday, November 12, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Q2 and H1 of FY26). The company is an active pharmaceutical ingredient (API) manufacturer based in Mumbai with a manufacturing facility in Lote Parshuram, Maharashtra. In line with insider trading rules, the trading window for designated persons and their immediate relatives is closed from October 1, 2025, until 48 hours after the results are declared on November 12, 2025.
This is a routine pre-results intimation with no material business announcement. Shareholders should watch the November 12 outcome for actual Q2/H1 FY26 numbers, which will be the key driver of near-term stock movement.